



Aquestive Therapeutics to Present at Two Upcoming Investor Conferences

May 13, 2019

WARREN, N.J., May 13, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' unmet needs and solve therapeutic problems, today announced that management will present at the 2019 RBC Capital Markets Global Healthcare Conference to be held in New York, NY on May 21-22, and the 20th Annual B. Riley FBR Institutional Investor Conference to be held in Beverly Hills, CA on May 22-23. Presentation times are as follows:



2019 RBC Capital Markets Global Healthcare Conference
Wednesday, May 22nd at 11:00 AM ET

20th Annual B. Riley FBR Institutional Investor Conference
Thursday, May 23rd at 11:30 AM PT

A webcast of the presentation will be available on the "Events and Presentation" page of the Investors section of the Company's website. A replay of each webcast will be available for 90 days following the event. For more information, please visit investors.aquestive.com.

About Aquestive Therapeutics

Aquestive Therapeutics is a specialty pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. Aquestive is advancing a late-stage proprietary product pipeline to treat CNS conditions and provide alternatives to invasively-administered standard of care therapies. The Company also collaborates with pharmaceutical partners to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven capabilities for drug development and commercialization.

Media inquiries:

Christopher Hippolyte
christopher.hippolyte@syneoshealth.com
212-364-0458

Investor inquiries:

Stephanie Carrington
stephanie.carrington@icrinc.com
646-277-1282

 View original content to download multimedia: <http://www.prnewswire.com/news-releases/aquestive-therapeutics-to-present-at-two-upcoming-investor-conferences-300848362.html>

SOURCE Aquestive Therapeutics